Friday, January 15, 2010

Vaxart Gets $3.5M

San Francisco-based Vaxart, a developer of oral vaccines, has raised nearly $3.5M out of an ongoing $12.5M funding round, the firm disclosed in a regulatory filing Thursday. Source of the new funding was not disclosed. The firm's pipeline currently included an annual influenza, avian influenza, and H1N1 vaccines. The firm has previously raised funding from Bay Partners, Life Science Angels, Quantum Technology Partners, and Sand Hill Angels. More information »